The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Decitabine improves patient outcomes in myelodysplastic syndromes: Results of a phase III randomized study
Abstract
BACKGROUND: Aberrant DNA methylation, which results in leukemogenesis, is frequent in patients with myelodysplastic syndromes (MDS) and is a potential target for pharmacologic therapy. Decitabine indirectly depletes methylcytosine and causes hypomethylation of target gene promoters. METHODS: A total of 170 patients with MDS were randomized to receive either decitabine at a dose of 15 mg/m 2 given intravenously over 3 hours every 8 hours for 3 days (at a dose of 135 mg/m 2 per course) and repeated every 6 weeks, or best supportive care. Response was assessed using the International Working Group criteria and required that response criteria be met for at least 8 weeks. RESULTS: Patients who were treated with decitabine achieved a significantly higher overall response rate (17%), including 9% complete responses, compared with supportive care (0%) (P < .001). An additional 12 patients who were treated with decitabine (13%) achieved hematologic improvement. Responses were durable (median, 10.3 mos) and were associated with transfusion independence. Patients treated with decitabine had a trend toward a longer median time to acute myelogenous leukemia (AML) progression or death compared with patients who received supportive care alone (all patients, 12.1 mos vs. 7.8 mos [P = 0.16]; those with International Prognostic Scoring System intermediate‐2/high‐risk disease, 12.0 mos vs. 6.8 mos [P = 0.03]; those with de novo disease, 12.6 mos vs. 9.4 mos [P = 0.04]; and treatment‐naive patients, 12.3 mos vs. 7.3 mos [P = 0.08]). CONCLUSIONS: Decitabine was found to be clinically effective in the treatment of patients with MDS, provided durable responses, and improved time to AML transformation or death. The duration of decitabine therapy may improve these results further. Cancer 2006. © 2006 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationCpG-rich islands and the function of DNA methylation
Bird, A. P. (1986) · Nature · doi:10.1038/321209a0 · Cited by 3,777
Saunthararajah, Y., Hillery, C. A., Lavelle, D., Molokie, R., Dorn, L., Bressler, L., Gavazova, S., Chen, Y.-H., Hoffman, R., & DeSimone, J. (2003) · Blood · doi:10.1182/blood-2003-05-1738 · Cited by 277
Cited by
Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in Cancer
Yang, X., Han, H., De Carvalho, D. D., Lay, F. D., Jones, P. A., & Liang, G. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.07.028 · Cited by 1,199
Yang, H., Bueso-Ramos, C., DiNardo, C., Estecio, M. R., Davanlou, M., Geng, Q.-R., Fang, Z., Nguyen, M., Pierce, S., Wei, Y., et al. (2014) · Leukemia · doi:10.1038/leu.2013.355 · Cited by 688
Self-citationEpigenomic alterations define lethal CIMP-positive ependymomas of infancy
Mack, S. C., Witt, H., Piro, R. M., Gu, L., Zuyderduyn, S., Stütz, A. M., Wang, X., Gallo, M., Garzia, L., Zayne, K., et al. (2014) · Nature · doi:10.1038/nature13108 · Cited by 607
Eprenetapopt (APR-246) and Azacitidine in TP53 -Mutant Myelodysplastic Syndromes
Sallman, D. A., DeZern, A. E., Garcia-Manero, G., Steensma, D. P., Roboz, G. J., Sekeres, M. A., Cluzeau, T., Sweet, K. L., McLemore, A., McGraw, K. L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02341 · Cited by 465
“PRD (63-97) DBD (102-292) TET (323-356) REG (363-393) TAD2 (43-62) TAD1 (1-42) CR mCR + HI mCR HI SD PD NR/NE”
Self-citationThe landscape and therapeutic relevance of cancer-associated transcript fusions
Yoshihara, K., Wang, Q., Torres-Garcia, W., Zheng, S., Vegesna, R., Kim, H., & Verhaak, R. G. W. (2015) · Oncogene · doi:10.1038/onc.2014.406 · Cited by 450
Guo, S.-W. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap064 · Cited by 328
Traina, F., Visconte, V, Elson, P., Tabarroki, A., Jankowska, A. M., Hasrouni, E., Sugimoto, Y., Szpurka, H., Makishima, H., O'Keefe, C. L., et al. (2014) · Leukemia · doi:10.1038/leu.2013.269 · Cited by 269
Sekeres, M. A., Schoonen, W. M., Kantarjian, H., List, A., Fryzek, J., Paquette, R., & Maciejewski, J. P. (2008) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djn349 · Cited by 248
Self-citationSekeres, M. A., Othus, M., List, A. F., Odenike, O., Stone, R. M., Gore, S. D., Litzow, M. R., Buckstein, R., Fang, M., Roulston, D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2510 · Cited by 237
Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine
Liu, M., Ohtani, H., Zhou, W., Ørskov, A. D., Charlet, J., Zhang, Y. W., Shen, H., Baylin, S. B., Liang, G., Grønbæk, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612262113 · Cited by 225
Alves, R., Gonçalves, A. C., Rutella, S., Almeida, A. M., De Las Rivas, J., Trougakos, I. P., & Sarmento Ribeiro, A. B. (2021) · Cancers · doi:10.3390/cancers13194820 · Cited by 204
Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S., Tanaka, T. N., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01794 · Cited by 188
Self-citationDNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia
Metzeler, K. H., Walker, A., Geyer, S., Garzon, R., Klisovic, R. B., Bloomfield, C. D., Blum, W., & Marcucci, G. (2012) · Leukemia · doi:10.1038/leu.2011.342 · Cited by 186
Epigenetic cancer therapy: rationales, targets and drugs
Rius, M., & Lyko, F. (2012) · Oncogene · doi:10.1038/onc.2011.601 · Cited by 157
Molecular mechanism for USP7-mediated DNMT1 stabilization by acetylation.
Cheng, J., Yang, H., Fang, J., Ma, L., Gong, R., Wang, P., Li, Z., & Xu, Y. (2015) · Nature Communications · doi:10.1038/ncomms8023 · Cited by 158
Garcia‐Manero, G., Montalban‐Bravo, G., Berdeja, J. G., Abaza, Y., Jabbour, E., Essell, J., Lyons, R. M., Ravandi, F., Maris, M., Heller, B., et al. (2017) · Cancer · doi:10.1002/cncr.30533 · Cited by 104
Self-citationHayashi, M., Nomoto, S., Hishida, M., Inokawa, Y., Kanda, M., Okamura, Y., Nishikawa, Y., Tanaka, C., Kobayashi, D., Yamada, S., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-108 · Cited by 101
Cellular senescence in gastrointestinal diseases: from pathogenesis to therapeutics
Frey, N., Venturelli, S., Zender, L., & Bitzer, M. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.146 · Cited by 97
Natsume, A., Wakabayashi, T., Tsujimura, K., Shimato, S., Ito, M., Kuzushima, K., Kondo, Y., Sekido, Y., Kawatsura, H., Narita, Y., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23407 · Cited by 93
Zeidan, A. M., Wang, R., Wang, X., Shallis, R. M., Podoltsev, N. A., Bewersdorf, J. P., Huntington, S. F., Neparidze, N., Giri, S., Gore, S. D., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001779 · Cited by 93
Yamazaki, J., Jelinek, J., Lu, Y., Cesaroni, M., Madzo, J., Neumann, F., He, R., Taby, R., Vasanthakumar, A., Macrae, T., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-0739 · Cited by 89
Self-citationSaunthararajah, Y. (2013) · Hematology · doi:10.1182/asheducation-2013.1.511 · Cited by 79
Hunter, A. M., Komrokji, R. S., Yun, S., Al Ali, N., Chan, O., Song, J., Hussaini, M., Talati, C., Sweet, K. L., Lancet, J. E., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003508 · Cited by 76
Current and emerging strategies for management of myelodysplastic syndromes
Saygin, C., & Carraway, H. E. (2021) · Blood Reviews · doi:10.1016/j.blre.2020.100791 · Cited by 70
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
Spinner, M. A., Aleshin, A., Santaguida, M. T., Schaffert, S. A., Zehnder, J. L., Patterson, A. S., Gekas, C., Heiser, D., & Greenberg, P. L. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001934 · Cited by 40
Epigenetic reversal of acquired resistance to 5-fluorouracil treatment
Humeniuk, R., Mishra, P. J., Bertino, J. R., & Banerjee, D. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0717 · Cited by 28
Optimizing Therapy for Iron Overload in the Myelodysplastic Syndromes: Recent Developments
Leitch, H. A. (2011) · Drugs · doi:10.2165/11585280-000000000-00000 · Cited by 17
Metafuni, E., Chiusolo, P., Laurenti, L., Sorà, F., Giammarco, S., Bacigalupo, A., Leone, G., & Sica, S. (2018) · Mediterranean Journal of Hematology and Infectious Diseases · doi:10.4084/mjhid.2018.005 · Cited by 14
Metadata
- Authors
- Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., Helmer, R., Shen, L., Nimer, S. D., Leavitt, R., Raza, A., & Saba, H.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2006-03-13
- Volume
- 106
- Issue
- 8
- Pages
- 1794-1803
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2081279521
- Cited by
- 1,530
- References
- 4
- FWCI
- 48.27
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
